Wechselwirkungen · Biktarvy
Biktarvy 30 mg/120 mg/15 mg film-coated tablets Biktarvy 50 mg/200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-139281 · Präparat HOS-098314
Medicinal product by Effects on medicinal product Recommendation concerning therapeutic areas/possible levels. co-administration with Biktarvy mechanism of interaction Mean percent change in AUC, Cmax, Cmin HERBAL PRODUCTS St. John’s wort (Hypericum Interaction not studied with any of Co-administration with St. John’s perforatum) the components of Biktarvy. wort is contraindicated, due to the Co-administration may decrease effect of St. John’s wort on the (Induction of CYP3A, UGT1A1, bictegravir and tenofovir bictegravir component of Biktarvy. and P-gp) alafenamide plasma concentrations. ANTI-INFECTIVES Antimycobacterials Rifampicin (600 mg once daily), Bictegravir: Co-administration is Bictegravir1 AUC: ↓ 75% contraindicated due to the effect of Cmax: ↓ 28% rifampicin on the bictegravir (Induction of CYP3A, UGT1A1, component of Biktarvy. and P-gp) Interaction not studied with tenofovir alafenamide. Co-administration of rifampicin may decrease tenofovir alafenamide plasma concentrations. Rifabutin (300 mg once daily), Bictegravir: Co-administration is not Bictegravir1 AUC: ↓ 38% recommended due to the expected Cmin: ↓ 56% decrease of tenofovir alafenamide. (Induction of CYP3A and P-gp) Cmax: ↓ 20%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T17:05:00Z · SHA-256 8ec4738243d92aa421e74b71a9bad453e15421c1f952d3be4e88479f189e0fe4 · Passage c4a553d4c5d6e143431ed5f36b5cee894100b353f2c9e23456e7242397f844a2 · Zeichen 3412–5363 im Abschnitt